Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,541 Mln
Revenue (TTM)
$220 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.5
Industry P/E
--
EV/EBITDA
-7.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.4
Face value
--
Shares outstanding
75,349,000
CFO
$-613.29 Mln
EBITDA
$-917.73 Mln
Net Profit
$-893.93 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SpringWorks Therapeutics (SWTX)
| 30.1 | 0.6 | 12.2 | 22.0 | 21.0 | 2.6 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
SpringWorks Therapeutics (SWTX)
| -1.0 | 40.3 | -58.0 | -14.5 | 88.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
SpringWorks Therapeutics (SWTX)
|
47.0 | 3,540.7 | 219.7 | -253.9 | -120.5 | -53.5 | -- | 8.5 |
| 4.0 | 258.3 | 0.0 | -106.7 | -- | -186.3 | -- | 8.1 |
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat),... an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Read more
Chief Financial Officer
Mr. Francis I. Perier Jr., M.B.A.
Chief Financial Officer
Mr. Francis I. Perier Jr., M.B.A.
Headquarters
Stamford, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of SpringWorks Therapeutics Inc (SWTX) is $46.99 (NASDAQ) as of 02-Jul-2025 09:30 EDT. SpringWorks Therapeutics Inc (SWTX) has given a return of 21.01% in the last 3 years.
Since, TTM earnings of SpringWorks Therapeutics Inc (SWTX) is negative, P/E ratio is not available.
The P/B ratio of SpringWorks Therapeutics Inc (SWTX) is 8.48 times as on 02-Jul-2025, a 115 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-10.38
|
5.57
|
|
2023
|
-8.25
|
4.28
|
|
2022
|
-5.92
|
-2.85
|
|
2021
|
-17.44
|
7.15
|
|
2020
|
-77.55
|
6.16
|
The 52-week high and low of SpringWorks Therapeutics Inc (SWTX) are Rs 62.00 and Rs 28.21 as of 03-Apr-2026.
SpringWorks Therapeutics Inc (SWTX) has a market capitalisation of $ 3,541 Mln as on 02-Jul-2025. As per SEBI classification, it is a Small Cap company.
Before investing in SpringWorks Therapeutics Inc (SWTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.